文献速递免疫规划

佐剂重组带状疱疹疫苗与其他成人疫苗联合接种:概述

Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview.
PubMed 文献 · Vaccine · 2024-02-28

本综述汇总五项随机、开放标签III期临床试验数据,评估佐剂重组带状疱疹疫苗(RZV)与流感疫苗、肺炎球菌疫苗、百白破疫苗及新冠mRNA-1273加强针联合接种的安全性、反应原性和免疫原性。共3974名≥50岁健康成人接种,联合接种组1973人、序贯接种组2001人。结果显示联合接种不显著改变反应原性、免疫原性或安全性,除百日咳杆菌黏附素外免疫应答均非劣效。

要点

  • RZV与多种成人疫苗联合接种的疫苗应答率与序贯接种相似。
  • 除百日咳杆菌黏附素外,联合接种对RZV和其他疫苗的免疫应答均非劣效。
  • 联合接种与序贯接种的局部和全身不良事件发生率总体相似。

核心结论

  • RZV与常规疫苗联合接种不显著改变RZV或联合疫苗的反应原性、免疫原性或安全性。
  • 医护人员应考虑将RZV与其他成人疫苗常规联合接种以提高疫苗接种覆盖率。

研究设计与样本

  • 综述汇总五项随机、开放标签III期临床试验数据,研究设计相似。
  • 联合接种疫苗包括四价季节性灭活流感疫苗(IIV4;NCT01954251)、23价肺炎球菌多糖疫苗(PPSV23;NCT02045836)、减量抗原百日咳-破伤风-无细胞百日咳疫苗(Tdap;NCT02052596)、13价肺炎球菌结合疫苗(PCV13;NCT03439657)和COVID-19 mRNA-1273加强针(NCT05047770)。
  • 合格参与者为≥50岁健康成人。
  • 五项试验共3974名参与者接种,联合接种组1973人、序贯接种组2001人。

主要发现

  • RZV疫苗应答率联合接种组范围为95.8-99.1%,序贯接种组范围为95.1-99.1%,两组相似。
  • 除百日咳杆菌黏附素外,联合接种相比序贯接种对RZV和其他疫苗的免疫应答均非劣效。
  • 主动报告局部和全身不良事件、非主动报告不良事件、严重不良事件或潜在免疫介导疾病的总发生率在联合接种或序贯接种后相似。
  • 肌痛是最常见的主动报告全身不良事件(联合接种组:38-64%;序贯接种组:30-59%)。
  • RZV与PPSV23联合接种后寒战和发热发生率(分别为16%和21%)高于序贯接种后(均为7%)。

临床怎么用

  • 医护人员应考虑将RZV与其他成人疫苗常规联合接种以提高疫苗接种覆盖率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV; Shingrix®, GSK) is a subunit vaccine that has been approved for the prevention of herpes zoster in adults. Co-administration of two vaccines in a single visit is a strategy to improve overall vaccine coverage. OBJECTIVES: This review aims to consolidate available clinical data on RZV co-administration, providing an overview of safety, reactogenicity and immunogenicity. METHODS: RZV co-administration data were obtained from five randomised, open-label, phase III clinical trials with similar study designs. The co-administered vaccines included: quadrivalent seasonal inactivated influenza vaccine (IIV4; NCT01954251), 23-valent pneumococcal polysaccharide vaccine (PPSV23; NCT02045836), reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine (Tdap; NCT02052596), 13-valent pneumococcal conjugate vaccine (PCV13; NCT03439657) and COVID-19 mRNA-1273 booster (NCT05047770). Eligible participants were healthy adults aged ≥50 years. RESULTS: A total of 3,974 participants were vaccinated (co-administration: 1,973; sequential: 2,001) across the five trials. Vaccine response rates to RZV were similar for co-administration (range: 95.8-99.1 %) and sequential groups (range: 95.1-99.1 %). Immune responses to RZV and the other vaccines (with the exception of pertactin) were non-inferior when the vaccines were co-administered compared with sequentially administered. Overall incidences of solicited local and general adverse events (AEs), unsolicited AEs, serious AEs or potential immune-mediated diseases were similar after co-administration or sequential administration. Myalgia was the most common solicited systemic AE (co-administration: 38-64 %; sequential: 30-59 %). Shivering and fever were more common after co-administration (16 % and 21 %, respectively) than after sequential administration (both 7 %) of RZV and PPSV23. CONCLUSIONS: Co-administration of RZV with routine vaccines does not significantly alter the reactogenicity, immunogenicity or safety of RZV or the co-administered vaccine. Healthcare practitioners should consider routine co-administration of RZV with other adult vaccines to improve vaccination coverage.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ali SO, Dessart C, Parikh R, et al. Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview. Vaccine. 2024. PMID: 38423814. doi:10.1016/j.vaccine.2024.02.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。